Biotech Stocks Heat Up: 6 Names Rally on Pipeline Updates and Investor Catalysts

Biotech had a solid Friday showing, with several names popping in after-hours trading as fresh catalysts and investor sentiment fueled gains.

Here’s what moved:

Butterfly Network (BFLY) closed up 14.22% to $2.65, then added another 6.04% after-hours to $2.81. The digital health play is banking on investor interest heading into the Evercore Healthcare Conference on December 2, where CEO Joseph DeVivo will host one-on-one meetings. The focus? Their handheld ultrasound tech and growth roadmap.

Citius Pharmaceuticals (CTXR) was the day’s biggest gainer at close—up 15.15% to $1.14—and didn’t slow down after-hours, climbing 7.90% to $1.23. The real catalyst: Citius Oncology inked a deeper partnership with Verix’s AI-powered Tovana platform to commercialize LYMPHIR (denileukin diftitox-cxdl), an FDA-approved immunotherapy for cutaneous T-cell lymphoma launching Q4 2025. This is the kind of infrastructure play that gets biotech investors excited.

Tempest Therapeutics (TPST) bounced back with a 4.86% after-hours gain to $3.67 after dropping 4.89% at close. The catalyst came earlier in the week: they’re acquiring dual-targeting CAR-T programs from Factor Bioscience (all-stock deal, closing early 2026). The prize? TPST-2003, a CD19/BCMA dual-CAR T therapy that extends their runway through mid-2027.

Other movers: ProQR Therapeutics (PRQR) +6.80% to $2.20 (no fresh news, pure sentiment), Perrigo (PRGO) +3.97% to $13.14, and Iterum Therapeutics (ITRM) +2.77% to $0.3969.

The pattern? M&A deals and partnership announcements are the biotech crowd’s favorite fuel right now.